Catalog No.
DHD10803
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-G2-kappa
Clonality
Monoclonal
Target
CD19, Differentiation antigen CD19, T-cell surface antigen Leu-12, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4
Concentration
6.03 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P15391
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
CD19, MOR-00208, MOR-208, XENP-5574, XMP-5574, XmAb-5574, Xmab-CD19, CAS: 1422527-84-1
Clone ID
Tafasitamab
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study, PMID: 32511983
Tafasitamab: First Approval, PMID: 32946059
Tafasitamab-cxix, PMID: 33016999
Tafasitamab, PMID: 33355731
Antibodies to watch in 2020, PMID: 31847708
Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma, PMID: 33202794
Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients, PMID: 33230948
The use of tafasitamab in diffuse large B-cell lymphoma, PMID: 34285786
Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma, PMID: 29444231
Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma, PMID: 33554668
Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor, PMID: 34414843
Diffuse Large B-cell Lymphoma Responds to Tafasitamab plus Lenalidomide, PMID: 34376434
A phase 2a, single-arm, open-label study of tafasitamab, a humanized, Fc-modified, anti-CD19 antibody, in patients with relapsed/refractory B-precursor cell acute lymphoblastic leukemia, PMID: 34343354
RE-MIND: Comparing tafasitamab + lenalidomide (L-MIND) with a real‑world lenalidomide monotherapy cohort in relapsed or refractory diffuse large B-cell lymphoma, PMID: 34433649
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, PMID: 34196165
Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL, PMID: 34354920
Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, PMID: 34407608
Enhancing CDC and ADCC of CD19 Antibodies by Combining Fc Protein-Engineering with Fc Glyco-Engineering, PMID: 33212776
Diffuse large B-cell lymphoma: new targets and novel therapies, PMID: 33820908
Lenalidomide in DLBCL: are we past the cell of origin?, PMID: 33989279
Incorporating Novel Targeted and Immunotherapeutic Agents in Treatment of B-Cell Lymphomas, PMID: 33770460
The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients, PMID: 23277329
Single-agent MOR208 salvage and maintenance therapy in a patient with refractory/relapsing diffuse large B-cell lymphoma: a case report, PMID: 27178351
For research use only. Not for human or drug use.
